Latest Industry Insights

In this interview, Dr Sudeb Dalai, senior medical director at Adaptive Biotechnologies, discusses the role that T-cell analysis may play in the diagnosis and treatment of diseases including SARS-CoV-2.

Here we summarize the webinar that was hosted by Klaus Hochleitner, PhD., which provides an overview of the important factors and considerations for robust lateral flow assay development.

When a tumor is surgically removed, small amounts of residual cancer can remain at a level that is undetectable with current imaging or blood-based approaches. In this interview, Technology Networks spoke with Asaf Zviran, co-founder and CEO of C2i Genomics to find out more about the company’s C2-Intelligence Platform for the detection of trace amounts of cancer.

A new body of work published in Science Translational Medicine outlines the preclinical testing of a microRNA-based gene therapy for Huntington's disease – AMT-130 – in minipigs.

In this interview, Technology Networks spoke with Neal Goodwin, PhD, Chief Scientific Officer at Teknova, to learn more about current bioprocessing and bioproduction trends in the cell and gene therapy space. Goodwin also discusses the impact of the COVID-19 pandemic on the biopharmaceutical sector and highlights how the industry has united to contribute to the development of vaccines at this critical time.

Progenity’s Christopher Wahl provides his insights into the research and work being done specifically with Progenity’s novel ingestible lab-in-a-capsule, PIL Dx.

As COVID-19 vaccination programs kick into gear, private and public workplaces are weighing up the risks and benefits of asking employees to return to the office. Affinity Empowering Inc, who offer workplace eHealth compliance services, have rolled out an end-to-end COVID-19 testing program to assist employers in their return to work protocols. We spoke to Affinity CEO Scott Storrer to find out more.

While S-ketamine has now become licensed as the antidepressant nasal spray Spravato, research into its mirror molecule has been more limited. Now, drug developers say that R-ketamine could potentially deliver a more targeted action with fewer side effects than its more popular twin.

Technology Networks recently interviewed Anthony V. Lemmo, to learn how rapid antigen tests work, how they compare to PCR tests and how they can be used to help slow the spread of SARS-CoV-2.

Technology Networks had the pleasure of speaking with Ki-Sung Kwon, head of the R&D unit at Celltrion to learn more about therapeutic versus preventive strategies against COVID-19 and the company's monoclonal antibody-based therapeutic – CT-P59 – that is currently being developed against COVID-19.